Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs GSK plc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.65 (market cap $157.51B), while GSK plc trades at $50.25 (market cap $102.60B). The key difference: Banco Bilbao Vizcaya Argentaria SA is the larger of the two by market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| BBVA | GSK | |
|---|---|---|
Market Cap | $157.51B | $102.60B |
Sector | Financials | Health |
52-Week High | $28.50 | $61.18 |
52-Week Low | $17.96 | $38.22 |
Dividend Yield | 3.8% | 3.57% |
Enterprise Value | — | $123.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.35 with a bullish technical outlook, supported by moving averages and a strong ADX trend indicator. The company reported robust Q2 2026 earnings, beating EPS estimates with $0.63 actual versus $0.59 expected, driven by loan growth and a new $2.3 billion share buyback announcement. Revenue reached $39.42 billion in 2025, with net income of $10.51 billion and a rising profit margin of 26.66%.
Outlook remains positive with analyst consensus leaning buy (53.85%) and a projected revenue increase to $42.5 billion in 2026. Key risks include regulatory probes in Spain and volatile cash flow trends, but strong profitability and institutional support suggest upside potential for investors seeking European bank exposure.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
